RET and medullary thyroid gland carcinoma: Exposure of LUAD-0002AS1 (NSCLC, KIF5B–RET), ECLC5B (NSCLC, tripartite motif-containing 33 (TRIM33)–RET) and TT cells (medullary thyroid carcinoma, RETC634W) to vepafestinib resulted in efficient downregulation of RET phosphorylation at Y905 and Y1062 and downstream effectors.